PATENT CLAIM ANALYSIS

Application Number: 16135945
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "144100"]

Abstract:
The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.

Claim (Index 20):
A method for treating liver fibrosis comprising administering to a subject in need thereof an effective amount of nitazoxanide (NTZ) or a pharmaceutically acceptable salt of NTZ, wherein the liver fibrosis is non-alcoholic steatohepatitis (NASH)-induced fibrosis.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 97.0
- Lexical Diversity: 1.28571
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15837889', '15841777', '15841981', '15842234', '15958713']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8711315227620511
- 35 USC 102 Novelty (BERT): 0.7300236768329285
- Combined Prediction Score: 0.8570207381691388
- Mean Citation Score: 815.5844239999999
- Max Citation Score: 864.43933
- Similarity Product: 807.1295488079116

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test